PGLYRP4: A Potential Drug Target and Biomarker for Peptidoglycan Recognition Protein I-beta

Target Name: PGLYRP4

NCBI ID: G57115

PGLYRP4

PGLYRP4: A Potential Drug Target and Biomarker for Peptidoglycan Recognition Protein I-beta

Abstract:

Peptidoglycan recognition protein I-beta (PGLYRP4) is a key regulator of cell-cell adhesion, migration, and invasion. PGLYRP4 has been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we review the current research on PGLYRP4, its potential drug targets, and its potential as a biomarker for disease diagnosis and treatment.

Introduction:

PGLYRP4 (peptidoglycan recognition protein I-beta) is a transmembrane protein that plays a critical role in cell-cell adhesion and signaling. It is composed of an N-terminal transmembrane domain, a catalytic center, and a C-terminal cytoplasmic domain. PGLYRP4 is involved in the formation and maintenance of tight junctions, which are essential for maintaining tissue structure and barriers. It is also involved in cell signaling, including the regulation of cell adhesion, migration, and invasion.

Drug Targets:

PGLYRP4 has been identified as a potential drug target due to its involvement in various diseases. PGLYRP4 has been shown to be involved in cancer progression, neurodegenerative diseases, and autoimmune disorders. PGLYRP4 has also been shown to be involved in the regulation of cell signaling, including the regulation of cell adhesion, migration, and invasion.

PGLYRP4 has been shown to be involved in the regulation of cell adhesion by interacting with various adhesion molecules, including cadherins and immunoglobulin-like cell adhesion molecules (Ig-CAMs). PGLYRP4 has also been shown to be involved in the regulation of cell migration and invasion by interacting with various signaling pathways, including the TGF-β pathway and the Wnt pathway.

Biomarkers:

PGLYRP4 has also been shown to be involved in the regulation of various biological processes, including cell signaling, cell adhesion, migration, and invasion. Therefore, PGLYRP4 has the potential to serve as a biomarker for disease diagnosis and treatment. PGLYRP4 has been shown to be involved in the regulation of cancer progression, neurodegenerative diseases, and autoimmune disorders.

Conclusion:

PGLYRP4 is a protein that plays a critical role in cell-cell adhesion, migration, and invasion. It has been implicated in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Therefore, PGLYRP4 has the potential to serve as a drug target and biomarker for disease diagnosis and treatment. Further research is needed to fully understand the role of PGLYRP4 in these diseases and to develop effective treatments.

Protein Name: Peptidoglycan Recognition Protein 4

Functions: Pattern receptor that binds to murein peptidoglycans (PGN) of Gram-positive bacteria. Has bactericidal activity towards Gram-positive bacteria. May kill Gram-positive bacteria by interfering with peptidoglycan biosynthesis. Binds also to Gram-negative bacteria, and has bacteriostatic activity towards Gram-negative bacteria. Plays a role in innate immunity

The "PGLYRP4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PGLYRP4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets